The heart failure market in the top 7 major markets is expected to reach $18.5 billion by 2034. In order to see whether or not levosimendan would be able to help treat these patients with Pulmonary ...
Prothena Corporation plc's phase 3 AFFIRM-AL trial for birtamimab in AL amyloidosis failed, leading to program termination and workforce reduction. Despite Phase 3 AL Amyloidosis trial failure, I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback